Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-08-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the fifth board of directors of 美康生物科技股份有限公司. It includes details about the approval of the 2024 semi-annual report and its summary, a special report on the use of raised funds, and a decision regarding termination of a cooperation agreement by a subsidiary. The document states that the reports have been reviewed and approved by the board and audit committee, but it does not contain the full semi-annual report or detailed financial statements itself. It also references that the full reports are published separately on the regulatory disclosure website. The document is primarily a board meeting resolution announcement, not the actual interim/quarterly report or financial statements. Therefore, it fits best under Board/Management Information (MANG) as it announces board decisions and approvals related to company reports and transactions.
2024-08-28 Chinese
2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company 美康生物科技股份有限公司 during the first half of 2024. It includes specifics on the amount raised, the use of funds over multiple years, the balance of funds, compliance with regulatory requirements, and detailed tables showing the allocation and usage of the raised capital. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "专项报告" (special report) on the storage and use of raised funds for the half-year period 2024. This type of document is a specialized report on capital raised and its usage, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim financial report, nor an earnings release or audit report. It is a substantive report on fundraising and capital usage, not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-08-28 Chinese
2024年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (517 characters) from a company about the disclosure of its 2024 half-year report. It states that the full half-year report and its summary have been approved and will be disclosed on the official disclosure website. The document itself does not contain the actual financial data or the full report, but rather informs investors about the availability of the report elsewhere. According to the 'MENU VS MEAL' rule, such a short notice announcing the publication of a report is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2024-08-28 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset values for the half-year period. It also includes shareholder information, changes in shareholding, and important company matters during the reporting period. The document length is 4105 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content matches the characteristics of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and includes actual financial statements and business updates. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2024
2024-08-28 Chinese
关于为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company to its wholly-owned subsidiaries. It includes specifics about guarantee amounts, related contracts, financial data of the subsidiaries, and compliance with regulatory requirements. The document is titled as an "announcement" and contains no comprehensive financial statements or management discussion typical of annual or interim reports. It is not a certification or a brief notice about report publication. The content focuses on a financing guarantee update, which aligns with capital or financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is about 4700 characters, sufficient for a substantive announcement but not a full financial report.
2024-08-28 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "美康生物科技股份有限公司 2024 年半年度报告全文" which translates to "Medical System Biotechnology Co., Ltd. 2024 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2024 to June 30, 2024. The content includes detailed financial data, management discussion and analysis, company overview, business segments, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.